• PRODUCTS
    • Assay Kit Platform & Formats
    • Reporter Assays By Receptor
    • Growth Factor Assays
    • Toxicology Kits
      • In Vitro Hepatotoxicity Assay Kit & Screening Services
      • Assay Kits & Services for Gene Expression Profiling
      • Human P-Glycoprotein / MDR1 Drug Interaction Assay Kit & Screening Services
    • Environmental Monitoring Assays
    • Animal Model Assays
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Receptor Profiling & Panels
    • Custom Assay Development
    • Environmental Testing Assays
    • Toxicology in The Drug Discovery and Development Process
  • RESOURCES
    • Nuclear Receptor Overview
    • Disease State Targets
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Articles, Blogs, and Posters
      • New Research Publications
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product Material Safety Data Sheets
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors
Search site...

± α β γ δ Δ ε ζ κ ω ö ® ™ µ

  • PRODUCTS
    • Assay Kit Platform & Formats
    • Reporter Assays By Receptor
    • Growth Factor Assays
    • Toxicology Kits
      • In Vitro Hepatotoxicity Assay Kit & Screening Services
      • Assay Kits & Services for Gene Expression Profiling
      • Human P-Glycoprotein / MDR1 Drug Interaction Assay Kit & Screening Services
    • Environmental Monitoring Assays
    • Animal Model Assays
    • INDIGlo Luciferase Detection Reagent
    • Live Cell Multiplex
  • SERVICES
    • Reporter Assay Services
    • Nuclear Receptor Profiling & Panels
    • Custom Assay Development
    • Environmental Testing Assays
    • Toxicology in The Drug Discovery and Development Process
  • RESOURCES
    • Nuclear Receptor Overview
    • Disease State Targets
      • Overview
      • Anemia & Kidney Disease
      • Autoimmune Disease & Inflammation
      • Cancer
      • Cardiovascular Disease
      • Diabetes
      • Endocrinology
      • NAFLD/NASH
      • Obesity
    • Articles, Blogs, and Posters
      • New Research Publications
      • Scientific Whitepapers from INDIGO
      • Scientific Posters from INDIGO
      • BLOG
    • Product Literature
      • INDIGO Technical Manuals
      • Product Material Safety Data Sheets
      • upcyte® Hepatocytes
    • FAQ
  • ABOUT
    • About INDIGO
    • Why INDIGO
    • Key Personnel
      • Board of Directors & Advisors
      • Management
    • Employment
    • INDIGO Press Releases
    • INDIGO in the News
  • CONTACT US
    • Contact INDIGO
    • Request a Quote
    • Ordering & Distributors
Print Friendly, PDF & Email

Live Cell Multiplex Assay Kits & Services

Product Family Product Number Product Description Technical Manual
LCMA LCM01 LCMA 1×96-wells Reagent Pack Technical Manual
LCM05 LCMA 5×96-wells Reagent Pack Technical Manual
LCM10 LCMA 10×96-wells Reagent Pack Technical Manual

Get Pricing

  • Background
  • Services
  • Format & Performance

The Live Cell Multiplex (LCM) Assay provides an efficient fluorescence-based method of quantifying the relative number of live cells resident in treated wells of an assay plate. While the LCM Assay may be performed as a stand-alone assay, it has been specifically optimized to be run in multiplex with any of INDIGO’s 96-well, 2x48-well, or 3x32-well Nuclear Receptor Reporter Assay System products.

The LCM assay allows users to validate their primary Nuclear Receptor Assay data by determining if their test compound treatments exert mitogenic, cytostatic or cytotoxic activities on the reporter cells. The occurrence of such adverse non-specific effects will always undermine the accurate assessment of a test compound’s potency and/or efficacy as a modulator of nuclear receptor function.

When screening test compounds for antagonist activities it is particularly important to quantify changes in the relative number of live reporter cells at the assay endpoint. Test compounds that exert cytostatic, cytotoxic, or cytolytic activities invariably generate “false-positive” results in an antagonist screen. In such cases, the observed drop in luciferase activity will be incorrectly attributed to inhibition of the nuclear receptor by the test compound. In reality, however, the treatment compound has pushed the reporter cells into division arrest, apoptosis, necrosis, or lysis.

The LCM assay allows user’s to validate their primary Nuclear Receptor Assay data by determining if their test compound treatments exert mitogenic, cytostatic or cytotoxic activities on the reporter cells. The occurrence of such adverse non-specific effects will always undermine the accurate assessment of a test compound’s potency and/or efficacy as a modulator of nuclear receptor function.

When screening test compounds for antagonist activities it is particularly important to quantify changes in the relative number of live reporter cells at the assay endpoint. Test compounds that exert cytostatic, cytotoxic, or cytolytic activities invariably generate “false-positive” results in an antagonist screen. In such cases, the observed drop in luciferase activity will be incorrectly attributed to inhibition of the nuclear receptor by the test compound. In reality, however, the treatment compound has pushed the reporter cells into division arrest, apoptosis, necrosis, or lysis.

Format

Live Cell Multiplex Format The fluorescence-based LCM Assay and the luminescence-based INDIGO NR Assay are performed sequentially using the same assay wells. The text in blue corresponds to the LCM Assay portion of the multiplex protocol. Text in black corresponds to the standard protocol used for each of INDIGO’s 96-well format Nuclear Receptor Reporter Assays.

Performance

Live Cell Multiplex performance RFU = % Live Cells. The LCM Assay provides a direct correlation between % RFU and % Live Cells in an assay well.

Request a Quote

Search

Search site...
Click to Insert Symbols in Search

α β γ δ Δ ε ζ κ ® ™ µ

Want More Information?

Resource Quick Links

  • Technical Manuals & Product Listing
  • Safety Data Sheets
  • Sample Study Report
  • Study Work Order Form

3006 Research Drive, Suite A1, State College, PA, USA 16801

+1 (814) 234-1919

  • Terms Conditions
  • Privacy Policy
  • Product Policies
  • Limited Use Disclosure

© 2022 INDIGO Biosciences, Inc. All Rights Reserved